Lisata Therapeutics Inc Stock Price, News & Analysis

Welcome to our dedicated page for Lisata Therapeutics news (Ticker: LSTA), a resource for investors and traders seeking the latest updates and insights on Lisata Therapeutics stock.

Lisata Therapeutics, Inc. (Nasdaq: LSTA) is a clinical-stage pharmaceutical company developing certepetide-based therapies for advanced solid tumors and other serious diseases. This news page aggregates company announcements, clinical trial updates and regulatory disclosures so readers can follow how Lisata’s certepetide program and related partnerships evolve over time.

Lisata’s recent news flow has focused on progress across multiple certepetide clinical studies, including the ASCEND Phase 2b trial in metastatic pancreatic ductal adenocarcinoma, the BOLSTER Phase 2a trial in cholangiocarcinoma, the CENDIFOX Phase 1b/2a trial in pancreatic, colon and appendiceal cancers, the iLSTA Phase 1b/2a trial in locally advanced non-resectable pancreatic ductal adenocarcinoma and a Phase 2a glioblastoma multiforme study. Press releases have highlighted preliminary efficacy and safety signals, tumor microenvironment findings and timelines for upcoming data readouts.

Investors and researchers can also see updates on Lisata’s business development activities, such as its global non-exclusive license agreement with Catalent, Inc. to use certepetide as a SMARTag® antibody-drug conjugate payload, and its strategic alliance with GATC Health to apply an AI-powered Multiomics Advanced Technology™ platform to drug discovery. Financial results releases provide context on operating expenses, cash runway and the company’s ability to support ongoing trials.

By reviewing the LSTA news feed on this page, readers can monitor clinical milestones, conference presentations, licensing developments and other corporate communications directly sourced from Lisata’s public announcements and related SEC-referenced materials.